Vanderbilt-Ingram Cancer Center (VICC) has entered into a multi-year research support and collaboration agreement with Incyte Corporation. The agreement will support basic and translational research to enable novel therapeutic approaches for patients with cancer. See press release.
News: Drug Discovery
Researchers at Vanderbilt University have discovered a new way to inhibit Hedgehog (Hh) signaling, an important regulatory pathway for vertebrate development – and cancer. Abnormal regulation of this pathway leads to several human malignancies, including small cell lung cancer and pancreatic cancer, and therefore it is a potential drug target for cancer. Small molecules have […]
Small interfering RNA (siRNA) molecules can suppress tumor growth and target cells otherwise untreatable by conventional therapeutics, but targeted, intracellular delivery is a significant limitation to siRNA translation. To deliver the siRNA molecules into tumor cells, researchers have packaged them in micelles that express folic acid, which is internalized by cancer cells that overexpress folate […]
Vanderbilt University researchers have discovered a cleft in a chromosome-binding protein that may hold the key to stopping most cancers in their tracks. The protein, WDR5, is a “docking station” for a family of transcription factors called MYC that is overexpressed in the majority of malignancies and which contributes to an estimated 100,000 cancer-related deaths […]
Two Vanderbilt-Ingram Cancer Center (VICC) leaders have been named to a panel of the Institute of Medicine (IOM) to help shape national policies on the use of biomarkers for targeted cancer therapies. Harold L. (Hal) Moses, M.D., Ingram Professor of Cancer Research and director emeritus of VICC, will chair the IOM’s ad hoc committee, Policy […]
The Lustgarten Foundation has awarded a $1.5 million Research Investigator Grant to Stephen Fesik, Ph.D., professor of Biochemistry, Pharmacology and Chemistry, for research designed to discover new drugs for the treatment of pancreatic cancer. This is Fesik’s second three-year award from the Lustgarten Foundation in support of his research targeting K-Ras, a protein mutated in […]
Two therapies already in clinical development as single agents may work in combination to treat many subtypes of melanoma, a recent study suggests.
Somatic mutations, which can occur in any cell except sperm or egg, are not inheritable. Several recent studies have demonstrated that disease-causing mutations commonly alter protein folding, protein stability and protein-protein interactions. It has been difficult, however, to determine which somatic mutations identified in tumor samples “drive” the cancer development and which are just “along […]
Vanderbilt University investigators have discovered a new molecular mechanism that regulates the dynamics of microtubules, which form the cell’s internal skeleton. The unexpected finding, reported in Developmental Cell, has implications for cancer drug discovery,
Three Vanderbilt-Ingram Cancer Center (VICC) investigators have been awarded breast cancer research grants totaling $830,000 from the Susan G. Komen organization.
Subscribe to our e-Newsletter to receive email updates: